One Biosciences Initiates LARYCARE Clinical Study, Its Second Discovery Program

The LARYCARE study aims at discovering new predictive biomarkers to treatment response and at developing new potential precision therapies in the larynx and hypopharynx carcinoma This study follows One Biosciences’ first discovery program initiated a year ago in partnership with Institut Curie investigating high-grade serous ovarian cancer The initiation of this study follows the completion … [Read more…]

ONWARD Reports Positive Topline Results from a Pivotal Study to Restore Arm and Hand Function in People With Spinal Cord Injury

Up-LIFT study achieves primary endpoint: Statistically significant and clinically meaningful improvement in upper extremity strength and functioni Improvement in arm and hand function is the highest priority among people with tetraplegiaii Up-LIFT is the first large-scale clinical study of non-invasive spinal cord stimulation technology ONWARD plans to submit for marketing approval in the U.S. and … [Read more…]

Revance Announces Pricing of $200.0 Million Upsized Public Offering of Common Stock

NASHVILLE, Tenn.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced the pricing of an upsized underwritten public offering of 8,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $25.00 … [Read more…]

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its B-cell lymphoma-2 (BCL2) inhibitor ICP-248, which is the Company’s fifth innovative drug to enter the clinical stage in the field of hematology, and also the 13th … [Read more…]

CANbridge Pharmaceuticals to Participate in Two Investor Conferences in September

BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (HKEX:1228) , a China and U.S.-based global biopharmaceutical company committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, today announced that it will be participating in two upcoming investor conferences. Morgan Stanley 20th Annual Global Healthcare Conference (New York) CEO, James … [Read more…]

PDC*line Pharma Presents First Clinical Results From Phase I/II trial With PDC*lung01 at ESMO 2022

Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumour response in Non-Small Cell Lung Cancer Combination of PDC*lung01 at low dose with pembrolizumab resulted in Objective Response Rate and Progression Free Survival at nine months of 66.7% LIÈGE, Belgium & GRENOBLE, France–(BUSINESS WIRE)–PDC*line … [Read more…]

Rapid Dose Therapeutics Provides Update on Failure to File Cease Trade Order

BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release dated August 29, 2022, the Company and its auditors are continuing to work diligently to complete the audit of the Company’s annual financial statements for the fiscal … [Read more…]

United Therapeutics Releases Its Annual Corporate Responsibility Report and Inaugural Public Benefit Report

Report available at corporateresponsibility.unither.com SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its third annual Corporate Responsibility Report with 2021 highlights, providing stakeholders important information regarding the company’s commitment to environmental, social, and governance (ESG) priorities. Contained within the report … [Read more…]

Aptar Appoints Matthew L. Trerotola to its Board of Directors

CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Matt Trerotola has joined its Board of Directors. Matt has served as the President and Chief Executive Officer for Enovis Corporation (formerly Colfax), an innovation-driven medical technology company, since … [Read more…]